The partners are also working together to validate the company's molecular testing technologies in various settings.

The firm revised its revenue guidance for full-year 2026 to a range of $802 million to $806 million, and its net loss for the year to a range of $42 million to $34 million.

HHS OIG issued five recommendations, including refunding the federal government $18.5 million, as well as additional refunds for other potential overpayments.

The Chicago-based company is developing a POC field-effect transistor (FET)-based analyzer that it plans initially to target to the fertility testing space.

The platform combines machine learning and sample preparation techniques with the firm's proprietary Raman spectral databases.

Staffing is an issue for the clinical lab industry writ large, but rapid growth in demand and quickly changing technology has made liquid biopsies a particularly tricky area.

An analyst acknowledged Abbott's diagnostics business faces some downside risks, but its medical technology business is buoyed by potential tailwinds.

SimpleScreen is for adults 45 years of age and above at average risk for colorectal cancer and requires a simple blood draw. The test detects signals associated with colorectal cancer from cell-free ...

Last week, readers were most interested in a story about Tempus' offer to buy cancer diagnostic firm Personalis for $1.5 billion.

The lab firm said it now expects full-year net revenue in the range of $11.95 billion to $12.05 billion, up from its previous guidance of $11.78 billion to $11.90 billion.

The tests are intended for infectious and chronic disease detection and diagnosis as well as to aid in routine health monitoring.

The second generation test can detect the Bundibugyo strain of the virus that currently poses a threat in the Democratic Republic of the Congo and nearby countries.